MWA
ALXN

Marshall Wace Asia’s Alexion Pharmaceuticals ALXN Stock Holding History

Marshall Wace Asia’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-14,255
Closed -$2.18M – 185
2021
Q1 		$2.18M Buy
+14,255
New +$2.21M 0.05% 106
2018
Q4 		– Sell
-35,528
Closed -$4.94M – 123
2018
Q3 		$4.94M Buy
+35,528
New +$4.46M 0.17% 69

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Marshall Wace Asia's ALXN Position: Q2 2021 in Review

Marshall Wace Asia sold out of Alexion Pharmaceuticals (ALXN) in Q2 2021, closing a stake of 14,255 shares — an estimated $2.18M sold.

Marshall Wace Asia first reported a position in ALXN in Q3 2018 and held it in 2 quarters. The position peaked at $4.94M in Q3 2018. 707 funds tracked by Wall St. Rank hold ALXN as of Q2 2021.

  • Marshall Wace Asia reported no remaining Alexion Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Marshall Wace Asia sold 14,255 Alexion Pharmaceuticals shares in Q2 2021, an estimated $2.18M.
  • Marshall Wace Asia first reported a position in Alexion Pharmaceuticals in Q3 2018 and held it in 2 quarters.
  • Marshall Wace Asia's Alexion Pharmaceuticals position peaked at $4.94M in Q3 2018.
  • 707 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2021.

Based on Marshall Wace Asia's 13F filing for Q2 2021, filed 13 Aug 2021.